evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer's disease.
55
mentions
- News 33
- X 15
- Blogs 4
- YouTube 2
- +1 more
